208 related articles for article (PubMed ID: 37996125)
1. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
[TBL] [Abstract][Full Text] [Related]
3. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
4. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
[TBL] [Abstract][Full Text] [Related]
7. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
8. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
[TBL] [Abstract][Full Text] [Related]
9. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
[TBL] [Abstract][Full Text] [Related]
11. Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden.
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Lindström U; Turesson C; Chatzidionysiou K; Lindqvist E; Knight A; Forsblad-d'Elia H; Askling J
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38151264
[TBL] [Abstract][Full Text] [Related]
12. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
[TBL] [Abstract][Full Text] [Related]
13. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
[TBL] [Abstract][Full Text] [Related]
17. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
18. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Frisell T; Bower H; Morin M; Baecklund E; Di Giuseppe D; Delcoigne B; Feltelius N; Forsblad-d'Elia H; Lindqvist E; Lindström U; Askling J;
Ann Rheum Dis; 2023 May; 82(5):601-610. PubMed ID: 36787994
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
Tsai JJ; Liu LT; Chen CH; Chen LJ; Wang SI; Wei JC
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479495
[TBL] [Abstract][Full Text] [Related]
20. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
